NCT04455711 is a NA clinical trial of Lidocaine Iv in Cough, sponsored by Ajou University School of Medicine.

Who is sponsoring NCT04455711?

NCT04455711 is sponsored by Ajou University School of Medicine.

What drugs are being tested in NCT04455711?

Interventions in NCT04455711: Lidocaine Iv, Remifentanil.

What condition does NCT04455711 study?

NCT04455711 studies Cough, Lidocaine.

Is NCT04455711 still recruiting?

NCT04455711 is currently status unknown. Last updated 2 July 2020.

Last reviewed 2020-07-02 · How we verify

NCT04455711

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Effect of Lidocaine on Smooth Emergence With Double Lumen Tube

Status unknown NA Last updated 2 July 2020

What this trial tests

NA trial testing Lidocaine Iv in Cough in 80 participants. Status unknown.

Timeline

1 July 2020

Primary endpoint
31 July 2021

31 July 2021

Quick facts

Lead sponsor	Ajou University School of Medicine
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	other
Enrollment	80
Start date	1 July 2020
Primary completion	31 July 2021
Estimated completion	31 July 2021
Sites	1 location across South Korea

Drugs / interventions tested

Lidocaine Iv — full drug profile →
Remifentanil — full drug profile →

Conditions studied

Cough — all drugs for Cough →
Lidocaine — all drugs for Lidocaine →

Sponsor

Ajou University School of Medicine

Who can join

Adults 19 to 75, male only, with Cough or Lidocaine. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Cough suppression during emergence and tracheal extubation from general anaesthesia has become an important issue as part of patient safety. Cough arised from the mechanical irritation of endotracheal tube and cuff could be accompanied by various adverse effects such as laryngospasm, hypertension, tachycardia, arrhythmia and increase of intracranial, intraocular, or intra-abdominal pressure. Several cough-preventing strategies have been proposed for smooth emergence, such as opioids, dexmedetomidine or lidocaine. Maintenance of remifentanil infusion during emergence has been reported to be an effective method in reducing cough and cardiovascular change without delay of recovery. In previous studies, the effetive effect-site concentraions for 95% of adults (EC95) for preventing cough are a little different depending on anaestheic agent, type of surgery and sex, ranged from 2.14 to 2.94 ng/ml. However, since most of these studies are for sing lumen endotracheal tube, similar preventing effect would not be expected for double lumen tube (DLT) because of its large diameter and long length. Another problem is higher concentration of remifentanil more than 2.5 ng/ml could not guarantee the safety after extubation. The efficacy of a single IV bolus of lidocaine for the prevention of cough has been the subject of numerous trials. Therefore, combined use of lidocaine and remifentanil could effectively prevent emergence cough for DLT without the risk of high concentration of remifentanil.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Lidocaine Iv

Trials testing the same drug.

NCT04614610 — Lidocaine Intravenous in the Emergency Department For Sickle Cell Crisis · Phase 2 · unknown
NCT04398316 — High Dose IV Lidocaine vs Hydromorphone for Abdominal Pain in the Emergency Department · Phase 4 · terminated
NCT04584749 — Lidocaine as an Anesthetic Adjuvant in Liver and Gastric Laparoscopic Surgery · Phase 4 · completed
NCT04535089 — Opioid Sparing Analgesia: Dexmedetomidine Versus Lidocaine for Intracranial Surgeries in Children · Phase 1, PHASE2 · completed
NCT04480281 — Intravenous Lidocaine in Open Lung Resection Surgery · Phase 4 · completed

Other recruiting trials for Cough

Currently open trials in the same condition.

NCT07171099 — Efficacy and Safety of Rengalin in the Treatment of ARVI Cough in Children · Phase 3 · recruiting
NCT06999577 — The Mechanism Versus PPI Trial · Phase 4 · recruiting
NCT06979141 — Dexmedetomidine, Magnesium Sulphate and Lidocaine for Cough Suppression After General Anesthesia · Phase 3 · recruiting
NCT06918756 — Development of a Cough Control Questionnaire (CCQ) · recruiting
NCT06878209 — Cough and Hemorrhoids · recruiting

Other Ajou University School of Medicine trials

Trials by the same sponsor.

NCT07101380 — Feasibility Study of 'SuperBrain BOOM' for Mild Cognitive Impairment Patients · NA · recruiting
NCT07395752 — Youth Suicide and Self-Harm Intervention: Clinical and Biological Outcomes Study · NA · recruiting
NCT06964217 — Immediate Fracture Risk After Antihypertensive Drug Initiation · not yet recruiting
NCT05751603 — Effectiveness on Smooth Extubation According to the Administration Time of Sugammadex · NA · not yet recruiting
NCT07479160 — Heart to Heart Web-based Communication Program for Heart Failure · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04455711 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Ajou University School of Medicine
Last refreshed: 2 July 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04455711.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing